• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CVS Health to buy Aetna in $69B merger

December 4, 2017 By Sarah Faulkner

CVS Health, AetnaCVS Health (NYSE:CVS) plans to buy health insurer Aetna (NYSE:AET) in a $69 billion merger, according to a report from The New York Times.

The deal comes as companies like Amazon (NSDQ:AMZN), which is reportedly trying to launch into the pharmacy business, are looking to change the way that consumers interact with the healthcare industry.

The chief executives of CVS and Aetna told news outlets that they plan to transform CVS’s pharmacies and clinics into community-based healthcare sites, where people can access care for a more reasonable price compared to a traditional visit to the doctor’s office.

Some critics have expressed concern that a vertical merger between the two companies could leave patients with fewer choices, especially if people with Aetna insurance are forced to go to CVS to fill a prescription or receive care.

Aetna CEO Mark Bertolini told The New York Times in an interview that the 10,000 CVS locations across the country provide a strategic advantage – they are already available and established within communities.

“CVS has the draw,” he said. “People trust their pharmacist.”

“We think of it as creating a new front door to healthcare in American” CVS Health CEO Larry Merlo told the news outlet.

CVS and Aetna have had a business relationship for seven years. According to reports, the two companies have been in talks over a merger for the last two months. Under the terms of the deal, CVS is slated to pay $207 per Aetna share. The companies expect that the merger will close in the second half of 2018, contingent upon approval by shareholders and regulators.

“If they can drive the adoption of the care delivery model, that’s a big deal,” Ana Gupte, a senior healthcare analyst for Leerink Partners, told The New York Times.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Aetna, amazon, CVS Health

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS